Table 2 Responses to therapy.

 N

32

30

27

 Mean (SD)

−2.0 (4.88)

−2.9 (4.02)

−4.8 (4.35)

 Min, max

−13.9, 6.3

−11.5, 5.9

−14.2, 2.9

 LS mean (SE)

−1.8 (0.74)

−3.2 (0.77)

−4.7 (0.81)

 Difference in LS means (SE) vs. placebo

−1.4 (1.06)

−2.9 (1.10)

 p-value

0.199

0.011

 N

32

30

27

 Mean (SD)

−8.3 (24.48)

−15.1 (22.78)

−24.1 (21.70)

 Min, max

−58.3, 46.6

−66.4, 35.3

−60.7, 22.1

 LS mean (SE)

−8.2 (4.09)

−15.9 (4.27)

−23.3 (4.53)

 p-value

0.196

0.016

Proportion achieving ≥5% absolute reduction in LFC**^a

8/33 (24%)

10/31 (32%)

12/30 (40%)

 p-value (Chi squared test)–post hoc

0.476

0.180

Proportion achieving ≥30% relative reduction in LFC**^a

7/33 (21%)

6/31 (19%)

10/30 (33%)

 p-value (Chi squared test)–post hoc

0.854

0.279

 N

32

29

26

 Mean (SD)

0.1 (0.82)

−0.3 (0.68)

−0.6 (0.96)

 Min, max

−1.4, 2.7

−1.8, 1.3

−2.9, 1.6

 LS mean (SE)

0.1 (0.14)

−0.4 (0.15)

−0.5 (0.16)

 p-value

0.029

0.005

 N

32

29

26

 Mean (SD)

−3 (19.2)

−4 (17.9)

−19 (27.2)

 Min, max

−50, 47

−33, 52

−89, 18

 LS mean (SE)

−2 (3.5)

−5 (3.7)

−16 (3.8)

 p-value

0.674

0.007

 N

32

29

26

 Mean (SD)

−2 (34.9)

−19 (26.4)

−30 (47.9)

 Min, max

−120, 124

−104, 21

−213, 18

 LS mean (SE)

−1 (4.6)

−20 (4.8)

−25 (5.0)

 p-value

0.005

<0.001

 N

29

27

25

 Mean (SD)

0 (20.5)

5 (34.1)

−16 (26.5)

 Min, max

−54, 48

−33, 147

−103, 31

 LS mean (SE)

1 (5.3)

1 (5.4)

−12 (5.5)

 p-value

0.955

0.072

 N

32

29

26

 Mean (SD)

18 (142.9)

−41 (136.3)

−24 (70.4)

 Min, max

−242, 632

−710, 98

−161, 154

 LS mean (SE)

19 (18.5)

−36 (19.4)

−24 (20.4)

 p-value

0.041

0.120

 N

32

29

27

 Mean (SD)

−1.1 (2.86)

−1.6 (3.02)

−3.5 (4.77)

 Min, max

−9.1, 3.8

−7.2, 5.9

−18.9, 4.5

 LS mean (SE)

−1.1 (0.64)

−1.6 (0.67)

−3.5 (0.70)

 p-value

0.554

0.012